Vimizim Disease Interactions

Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions during elosulfase alfa therapy and require additional monitoring. Patients with acute febrile or respiratory illness at the time of elosulfase alfa infusion may be at higher risk of life-threatening complications from hypersensitivity reactions. Careful consideration should be given to the patient's clinical status before elosulfase alfa administration and delaying the elosulfase alfa infusion should be considered.

Antihistamine pretreatment may increase the risk of apneic episodes in patients with sleep apnea; evaluation of airway patency should be considered before starting therapy. Patients using supplemental oxygen or continuous positive airway pressure during sleep should have these treatments readily available during elosulfase alfa infusion in case of an acute reaction, or extreme drowsiness/sleep induced by antihistamine use.